The Healthcare Investor, July 17
Greetings from the OneMedPlace editorial desk. This is our first edition of The Healthcare Investor, a newsletter which captures the most interesting healthcare articles from […]
The Healthcare Investor
Associated Press: Omeros Corporation — Award Winning Drug OMS824 Being Tested to Treat Huntington’s & Schizophrenia
Omeros Corporation (OMER) will soon begin two mid stage clinical trials on its drug OMS824 which has greatly increased its stock prices. The company is testing its drug as a treatment for Huntington’s disease toward the end of 2013 as well as trials involved the treatment of Schizophrenia.
Zacks: Peregrine Pharma – On the Verge of Releasing First Oncology Drug to Market
Peregrine Pharma (PPHM) recently announced that the US. Food and Drug Administration (FDA) has approved on the design for their Phase III registration trial for its oncology drug, Bavituximab.
Seeking Alpha: Cyclacel on the Verge of Becoming a Competitor for Big Pharma
Cyclacel Pharmaceuticals (CYCC) has been raising the eyebrows of many investors recently. This multi-marketed company has several potential medications in its pipeline, including: acute myeloid leukemia, Phase III; myelodysplastic syndrome, Phase II; solid tumors, Phase I.
Motley Fool: Oncolytics – Cancer Killing Virus enters Phase II Metastatic Melanoma Trial
A unique drug is on the right pathway to success, as Oncolytics Biotechnology (ONCY) is pushing Reolysin through the pipeline. David Williamson from Motley Fool reported that this cancer medication is based off a common virus, incidentally referred to as the new “Cancer-Killing Virus.”
Genomic Visions: Cempra – Oral and Intravenous Fluoroketolid to Improve Community Health
Cempra (CEMP) is a biotechnology company focused on creating a new antibiotic, which may be “the next generation oral and intravenous fluoroketolid.” The company’s main antibiotic, Solithromycin, is currently in a Phase III study for community acquired bacterial pneumonia, as well as a mid-stage trial for gonorrhea.
Biocentury: AVEO’s FDA Woes for Renal Cell Carcinoma Drug stops Astella’s Funding
AVEO Pharmaceuticals’ (AVEO) New Drug Application (NDA) with the FDA for their newly developed once a day oral medication to fight advanced renal cell carcinoma – known as Tivozanib – has hit a snag.Upon review, the FDA’s Oncologic Drugs Advisory Committee voted 13-1 against approval due to safety concerns.
News Medical: iBio Launch Platform Creates H7N9 Influenza Vaccine in Record Time
Influenza is a virus that is constantly changing and requires routine monitoring. Without the proper preparation, this advanced virus could develop in to a pandemic. IBio has produced a vaccine candidate for the newly emerging H7N9 influenza virus in a milestone time of 21 days.
Biocentury: Regeneron Using Interleukin Antibody Receptors for Asthma Medication
An estimated 25 million Americans suffer from Asthma, but current medications such as inhalers have been deemed ineffective for 10-20% of its users. Regneron (REGN) and Sanofi (SAN) have partnered to crease a new Asthma drug, Dupilumab.
Company Snapshot — Fibrocell Science: Autologous Cell Therapy, Aesthetic Treatment
The fibroblast cell is known to play key roles in extracellular matrix synthesis, production of collagen, and production of growth factors all of which support the skin, soft tissues, and aid in wound healing. Fibrocell Science (FCSC) is an autologous cell therapy company whose sole focus is the development of aesthetic, medical, and scientific application that involve the use of the fibroblast cell.